beta

RZLT

Rezolute Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.

Market Cap: 71.1 Million

Primary Exchange: NASDAQ

Website: https://www.rezolutebio.com/

Shares Outstanding: 39.6 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.226459589438974

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 287 trading days

From: 2020-11-09 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud